{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:29:53Z","timestamp":1768570193778,"version":"3.49.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T00:00:00Z","timestamp":1403654400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0101207","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T20:33:57Z","timestamp":1403728437000},"page":"e101207","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Reactive Oxygen Species and Autophagy Associated Apoptosis and Limitation of Clonogenic Survival Induced by Zoledronic Acid in Salivary Adenoid Cystic Carcinoma Cell Line SACC-83"],"prefix":"10.1371","volume":"9","author":[{"given":"Xi-Yuan","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,6,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/1097-0142(19860201)57:3<519::AID-CNCR2820570319>3.0.CO;2-V","article-title":"Adenoid cystic salivary gland carcinoma. A histopathologic review of treatment failure patterns","volume":"57","author":"HM Matsuba","year":"1986","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/archotol.129.11.1193","article-title":"Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck","volume":"129","author":"MW Sung","year":"2003","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hitre E, Budai B, Takacsi-Nagy Z, Rubovszky G, Toth E, et al. (2013) Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer.","DOI":"10.1038\/bjc.2013.468"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.oraloncology.2013.05.004","article-title":"Adenoid cystic carcinoma of the head and neck: A single-center analysis of 105 consecutive cases over a 30-year period","volume":"49","author":"S van Weert","year":"2013","journal-title":"Oral Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1365-2591.2012.02079.x","article-title":"Multiple osteolytic lesions of intraosseous adenoid cystic carcinoma in the mandible mimicking apical periodontitis","volume":"45","author":"M Grimm","year":"2012","journal-title":"Int Endod J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hed.10126","article-title":"Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up","volume":"24","author":"JE van der Wal","year":"2002","journal-title":"Head Neck"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5858\/2009-0527-RS.1","article-title":"Adenoid cystic carcinoma","volume":"135","author":"J Jaso","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archotol.125.2.149","article-title":"Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality","volume":"125","author":"J Fordice","year":"1999","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.molmed.2004.05.007","article-title":"Bisphosphonates: new therapeutic agents for the treatment of bone tumors","volume":"10","author":"D Heymann","year":"2004","journal-title":"Trends Mol Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1349-7006.2011.02113.x","article-title":"Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer","volume":"103","author":"M Zhao","year":"2012","journal-title":"Cancer Sci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/RHU.0b013e318188b1f3","article-title":"Paget disease of bone: therapeutic options","volume":"14","author":"SL Silverman","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"DM Black","year":"2007","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"RE Coleman","year":"2004","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/TCRM.S2707","article-title":"Zoledronic acid in the management of metastatic bone disease","volume":"4","author":"TJ Polascik","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"JR Green","year":"2003","journal-title":"Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6600986","article-title":"Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro","volume":"88","author":"P Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"T Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref18","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"E Corey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10495-008-0211-z","article-title":"The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis","volume":"13","author":"L Sewing","year":"2008","journal-title":"Apoptosis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"JR Berenson","year":"2005","journal-title":"Oncologist"},{"key":"ref21","unstructured":"Li SL (1990) [Establishment of a human cancer cell line from adenoid cystic carcinoma of the minor salivary gland]. Zhonghua Kou Qiang Yi Xue Za Zhi 25: 29\u201331, 62."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.oraloncology.2013.07.012","article-title":"Transforming growth factor-beta and epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma","volume":"49","author":"L Dong","year":"2013","journal-title":"Oral Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0022034511401407","article-title":"TGF-beta1 promotes migration and invasion of salivary adenoid cystic carcinoma","volume":"90","author":"L Dong","year":"2011","journal-title":"J Dent Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0304-3959(99)00294-8","article-title":"Synergistic effect of cholecystokinin octapeptide and angiotensin II in reversal of morphine induced analgesia in rats","volume":"85","author":"NL Han","year":"2000","journal-title":"Pain"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)29450-7","article-title":"Drug synergism: its detection and applications","volume":"298","author":"RJ Tallarida","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0304-3959(92)90193-F","article-title":"Statistical analysis of drug combinations for synergism","volume":"49","author":"RJ Tallarida","year":"1992","journal-title":"Pain"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Tallarida RJ (1992) A further comment on testing for drug synergism. Pain 51: 381\u2013382; author reply 383\u2013387.","DOI":"10.1016\/0304-3959(92)90225-Z"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/1947601912440575","article-title":"Quantitative methods for assessing drug synergism","volume":"2","author":"RJ Tallarida","year":"2011","journal-title":"Genes Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40261-012-0041-1","article-title":"Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice","volume":"33","author":"P Sieber","year":"2013","journal-title":"Clin Drug Investig"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/14656566.2011.562201","article-title":"Zoledronic acid for prevention and treatment of osteoporosis","volume":"12","author":"C Recknor","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CMAR.S27693","article-title":"Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis","volume":"4","author":"A Richhariya","year":"2012","journal-title":"Cancer Manag Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3760\/cma.j.issn.0366-6999.20122385","article-title":"Zoledronic acid inhibits growth of hepatocellular carcinoma cells in vitro and in vivo","volume":"126","author":"Q Liu","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1475-2867-12-48","article-title":"Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid","volume":"12","author":"T Ibrahim","year":"2012","journal-title":"Cancer Cell Int"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3892\/ol.2012.723","article-title":"Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells","volume":"4","author":"J Chang","year":"2012","journal-title":"Oncol Lett"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2106\/JBJS.H.01679","article-title":"Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines","volume":"92","author":"P Zwolak","year":"2010","journal-title":"J Bone Joint Surg Am"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.juro.2010.11.045","article-title":"Zoledronic acid induces autophagic cell death in human prostate cancer cells","volume":"185","author":"JF Lin","year":"2011","journal-title":"J Urol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","article-title":"Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line","volume":"44","author":"M Di Salvatore","year":"2011","journal-title":"Cell Prolif"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.archoralbio.2011.11.015","article-title":"Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes","volume":"57","author":"H Ohnuki","year":"2012","journal-title":"Arch Oral Biol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bcp.2009.04.004","article-title":"Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells","volume":"78","author":"AA Romani","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.lungcan.2007.08.026","article-title":"Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers","volume":"59","author":"YY Li","year":"2008","journal-title":"Lung Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/1477-3163.75723","article-title":"Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers","volume":"10","author":"H Almubarak","year":"2011","journal-title":"J Carcinog"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Li XY, Lin YC, Huang WL, Lin W, Wang HB, et al. (2012) Zoledronic acid inhibits human nasopharyngeal carcinoma cell proliferation by activating mitochondrial apoptotic pathway. Med Oncol.","DOI":"10.1007\/s12032-012-0281-1"},{"key":"ref43","first-page":"233","article-title":"Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents","volume":"24","author":"K Koto","year":"2010","journal-title":"Oncol Rep"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.4161\/cbt.7.12.7067","article-title":"Cancer cell killing via ROS: to increase or decrease, that is the question","volume":"7","author":"J Wang","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3892\/ijo.2012.1735","article-title":"Zoledronic acid significantly enhances radiationinduced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling","volume":"42","author":"K Koto","year":"2013","journal-title":"Int J Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1038\/cddis.2013.406","article-title":"Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways","volume":"4","author":"F Bruzzese","year":"2013","journal-title":"Cell Death Dis"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","article-title":"What is synergy?","volume":"41","author":"MC Berenbaum","year":"1989","journal-title":"Pharmacol Rev"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"WR Greco","year":"1995","journal-title":"Pharmacol Rev"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"SP Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3892\/ijo.2013.1809","article-title":"Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines","volume":"42","author":"T Ibrahim","year":"2013","journal-title":"Int J Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000093006","article-title":"Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents","volume":"70","author":"DR Budman","year":"2006","journal-title":"Oncology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cellbi.2007.02.004","article-title":"Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study","volume":"31","author":"OH Ozturk","year":"2007","journal-title":"Cell Biol Int"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0101207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T13:20:40Z","timestamp":1746278440000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0101207"}},"subtitle":[],"editor":[{"given":"Ya","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,25]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0101207","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,25]]}}}